Results 51 to 60 of about 148,446 (303)
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang +6 more
wiley +1 more source
This study evaluated effectiveness and safety of apixaban versus warfarin among venous thromboembolism patients at high-risk of bleeding (defined as having at least one of the following bleeding risk factors: ≥75 years; used antiplatelet, NSAIDs, or ...
Alexander T Cohen +9 more
doaj +1 more source
Hormone replacement therapy [PDF]
Martha Hickey, Jane Elliott, Sonia Louise ...
Davison, S., Elliott, C., Hickey, M.
core +2 more sources
This single‐center retrospective study evaluated perioperative outcomes after hepatectomy in 749 patients, including 140 receiving ATT, using propensity score matching to compare ATT and non‐ATT cohorts. Under standardized perioperative management, ATT did not increase major bleeding, transfusion, or severe morbidity overall; however, within the ATT ...
Haruki Mori +9 more
wiley +1 more source
Surgical embolectomy for acute massive pulmonary embolism: state of the art [PDF]
Massive pulmonary embolism (PE) is a severe condition that can potentially lead to death caused by right ventricular (RV) failure and the consequent cardiogenic shock.
De Bellis, Antonio +8 more
core +1 more source
Unlike deceased‐donor liver transplantation, living‐donor liver transplantation (LDLT) for Budd‐Chiari Syndrome (BCS) presents distinctive challenges in hepatic venous (HV)‐outflow reconstruction because diseased HV–inferior vena cava (IVC) cannot be entirely replaced with healthy donor vessels.
Koichiro Hata +4 more
wiley +1 more source
Platelet count measured prior to cancer development is a risk factor for future symptomatic venous thromboembolism: the Tromsø Study. [PDF]
BACKGROUND: Elevated platelet count is associated with risk of venous thromboembolism in cancer patients initiating chemotherapy. It is not known whether this risk by platelet count is causal or merely reflects the malignant disease.
Hilde Jensvoll +3 more
doaj +1 more source
Reshaping medical education: Performance of ChatGPT on a PES medical examination
BACKGROUND: We are currently experiencing a third digital revolution driven by artificial intelligence (AI), and the emergence of new chat generative pre-trained transformer (ChatGPT) represents a significant technological advancement with profound ...
Simona Wójcik +5 more
doaj +1 more source
Joint effects of cancer and variants in the factor 5 gene on the risk of venous thromboembolism
Venous thromboembolism occurs frequently in cancer patients. Two variants in the factor 5 gene (F5), rs6025 encoding for the factor V Leiden mutation R506Q, and rs4524 encoding K858R, have been found to be associated with venous thromboembolism.
Olga V. Gran +9 more
doaj +1 more source
Forty-One-Year-Old Man with Pulmonary Embolism 5 Months After COVID-19
Background: Hypercoagulation is one of the striking features of COVID-19. Patients hospitalized with COVID-19 are at high risk for venous thromboembolism. However, it is unknown if the risk for venous thromboembolism persists after discharge.
Muhanad Taha +4 more
doaj +1 more source

